Biopure (MM) (NASDAQ:BPURD)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Biopure (MM) Charts. Click Here for more Biopure (MM) Charts.](/p.php?pid=staticchart&s=N%5EBPURD&p=8&t=15)
Biopure Regains Nasdaq Listing Compliance
CAMBRIDGE, Mass., June 15 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPURD; BPUR) announced today that it has received notification from
The Nasdaq Stock Market that the company has regained compliance with the $1.00
minimum bid price requirement for continued listing on the Nasdaq National
Market, pursuant to Marketplace Rule 4450(a)(5).
Biopure Corporation
Biopure Corporation develops and manufactures intravenously administered
pharmaceuticals, called oxygen therapeutics, that deliver oxygen to the body's
tissues. The company is developing Hemopure(R) [hemoglobin glutamer - 250
(bovine)], or HBOC-201, for a potential indication in cardiovascular ischemia
and, in collaboration with the U.S. Naval Medical Research Center, for an out-
of-hospital trauma indication. The product is approved in South Africa for
treating surgery patients who are acutely anemic and for eliminating, delaying
or reducing allogeneic red blood cell transfusions in these patients. Hemopure
has not been approved for sale in any other jurisdictions, including the United
States or the European Union. Biopure's veterinary product Oxyglobin(R)
[hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic
approved by the U.S. Food and Drug Administration and the European Commission,
is indicated for the treatment of anemia in dogs.
Contact: Douglas Sayles
Biopure Corporation
(617) 234-6826
DATASOURCE: Biopure Corporation
CONTACT: Douglas Sayles of Biopure Corporation, +1-617-234-6826,
Web site: http://www.biopure.com/
Company News On-Call: http://www.prnewswire.com/comp/131224.html